In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Basilea/Astellas Agree To Change Primary Endpoint Of Phase III Aspergillosis Trial
You may also be interested in...
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.